Glucagon-like peptide-1 (GLP-1) agonists, also referred to as incretin mimetics or GLP-1 analogs, constitute a class of medications initially used in the management of type 2 diabetes mellitus (T2DM). This evidence concerns the gene GLP1R and diabetes mellitus.